Topcon to Attend EURETINA 2019 Meeting
Topcon Europe Medical, a leading provider of medical devices and software solutions for the European eye care community, is excited to announce its participation in EURETINA 2019, the European Society of Retinal Specialists’ annual congress, which has become internationally renowned as the largest retina meeting worldwide.
On 5-8 September, thousands of vitreoretinal and macula specialists will gather at the Palais des Congrès de Paris in France to share information on the latest trends and advances in vitreoretinal surgery and the diagnosis and treatment of retinal diseases including macular degeneration and diabetic retinopathy. Topcon will be located in the Exhibit Hall, Level 2 at Booth #219 and will showcase its latest innovative technology solutions for today’s retina specialists including the Triton Swept Source OCT, the newly released Maestro Fully Automated OCT with Angiography, Artificial Intelligence systems, the all new Topcon Signal Hand-held Camera, and the PASCAL Laser Systems.
The EURETINA Congress will also mark the debut of Topcon Harmony, the next generation software in eye care data management, within Europe. This browser-based software features faster access to patient exam data and allows examination devices, independent of device brand and type, to be integrated into the software and the examination results to be viewed side-by-side within a single screen. Visit Topcon Booth #219 during EURETINA to attend one of our data management workshops or to view a live demonstration of the NEW Topcon Harmony.
In addition to its booth display, Topcon will offer SS-OCT & OCTA workshops in its booth on Friday and Saturday. Experts will give 30 minute demonstrations. Advanced registration for the workshops is required at: www.topcon-medical.eu/eu/workshop. Furthermore, on 5 September at 13:00, Topcon will present a lunch symposium in the Amphitheatre Havane entitled “Superior Visualization with Swept Source OCT and OCT Angiography.” Pearse Keane, MD of Moorfields Eye Hospital, UK, will serve as the moderator, with Professor Hoyng of Radboud University in the Netherlands, Vasilios Papastefanou, MD, PhD of the UK, and Professor Alain Gaudric of France rounding out the panel. Topics to be discussed include utilizing SS- OCT and OCT Angiography for challenging clinical cases including microaneurysms, diabetic retinopathy and central serous chorioretinopathy. For more information on the symposium, please visit https://www.topcon-medical.eu/eu/pages/240-satellite-meeting-at-euretina.html
Topcon is a comprehensive diagnostic device manufacturer within the worldwide eye care community. It introduced the world’s first commercial back-of-the-eye Spectral Domain (SD) and multimodal Swept Source (SS) optical coherence tomography (OCT) systems, which have driven innovation in eye care.
Most recently, to develop the most efficient, pragmatic and state-of-the-art solutions, Topcon formed a new strategic division, Topcon Healthcare Solutions, whose primary objective is to create world-class software solutions for the eye care industry and beyond. The company's products enable the collection and visualization of a wide range of imaging and clinical data while providing quantitative and clinical analysis capabilities.
Topcon’s software gives clinicians access to patient exam data captured from OCTs, Visual Fields, Fundus Cameras, and other Topcon and third-party devices. Topcon leverages its new data management system called Harmony, where practitioners gain access to both DICOM and non-DICOM information stored in a central, cloud-based environment. Additionally, Topcon now provides an integrated service that connects practitioners to an extensive network of reading services to assist in the management of sight-threatening eye diseases.
Topcon Europe Medical BV
Phone: +31 (0)10 458 50 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes23.9.2019 09:00:00 EEST | Press release
Masimo (NASDAQ: MASI) announced today that in a study published in Injury, researchers used Masimo SpHb® – noninvasive, continuous hemoglobin monitoring – to investigate possible delays in the detection of perioperative anemia assessed using invasive, intermittent laboratory hemoglobin values in elderly patients undergoing hip fracture surgery.1 In addition, they investigated associations between a) this delay and cumulative perioperative time with anemia, monitored using SpHb, and b) patient outcomes (postoperative delirium and mortality or severe complications). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190922005060/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Dr. Christopher G. Clemmesen and colleagues at Copenhagen University Hospital in Denmark sought to investigate the impact of anemia during surgery on patient outcomes – and whether noninvasive hemoglobin monitoring using Masimo SpHb might provide an e
Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis1,2,3,423.9.2019 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced first results from the ENGAGE study which reports that simultaneous treatment with Dysport of both upper and lower limb spasticity in adult patients along with a Guided Self-rehabilitation Contract (GSC) – a personalized diary-based rehabilitation program – improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.1 Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first study to investigate treatment with Dysport in patients with spastic hemiparesis in both upper and lower limbs in combination with GSC. The primary efficacy endpoint of this international, prospective, single-arm study was the percentage of patients classified as responders at week six after the second injection, according to the CXA in the primary treatment target (PTT) limb.1 Professor Jean-Miche
Source Photonics Announces a Comprehensive Portfolio of 50Gb/s Optical Transceivers for 5G Mid-Haul Applications23.9.2019 02:48:00 EEST | Press release
Source Photonics, a market leader of optical transceivers for wireless applications, announces a comprehensive portfolio of 50Gb/s products serving 5G mid-haul applications. Source Photonics’ product portfolio leverages 30 years of high-speed optical transceiver development and high-volume shipments into wireless, datacenter and routing applications, resulting in a broad portfolio of optical transceivers supporting data rates ranging from 125Mb/s to 400Gb/s and transmitting between 300m and 40 km. Source Photonics has leveraged early investments in signal integrity, firmware development, and uncooled high speed DML packaging to release the industry’s most broad 50G product portfolio. 50Gb/s, selected as the mid-haul data rate, provides mid-haul bandwidth requirements not supported by 25Gb/s while also offering meaningful economic advantages over traditional 100Gb/s transceivers. Furthermore, 50Gb/s data rate products support bi-directional applications, where fiber availability is scar
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis23.9.2019 02:01:00 EEST | Press release
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA). CT-P13 SC is the subcutaneous version of Remsima® (biosimilar infliximab, CT-P13). This recommendation will now be reviewed by the European Commission, which has the authority to approve medicines in the EU. A subcutaneous formulation has the potential to enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration.1,2 “Today’s positive CHMP opinion brings us one step closer to providing a personalised treatment approach for people living with rheumatoid arthritis. This marks an important milestone for our business providing people with a new route of administration, and a novel formulation of infliximab,” said Hyoung-Ki
Source Photonics Demonstrates a Full 400G Product Portfolio at ECOC 201923.9.2019 02:01:00 EEST | Press release
Source Photonics, a leading vendor of optical connectivity products for Access and Datacom applications, will demonstrate its complete 400G portfolio with industry partners at ECOC 2019 from September 23-25. Source Photonics has added a wide range of new products to its industry leading portfolio of single-mode products for datacenter and routing applications. The new products leverage the company’s multi-year investment in 28Gbaud and 53Gbaud PAM4 technology and support 400G applications for reaches from 500m up to 40km in small form factor transceivers. Source Photonics’ portfolio of Datacenter and Routing products includes: 400G-DR4 supporting 400GE links over 500m as well as an enhanced reach of up to 2 km (4x100G-FR) with support for breakout into 100G-DR/FR 400G-LR8 supporting 400GE links up to 10 km 400G-ER8 supporting 400GE links up to 40km as technology demonstration “Successful interoperability between optical transceivers and hosts is crucial to rolling out the next higher d
Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom